Tilray Shares Continue Downward Spiral Amid Regulatory Battles

Tilray’s stock is experiencing a severe downturn, with consecutive trading sessions delivering significant blows to its market value. The cannabis producer’s shares fell an additional 4.7% today, building on yesterday’s substantial 4.39% decline. This persistent selling pressure indicates a definitive shift in investor sentiment toward the company.

Despite reporting quarterly revenue of $209.5 million that surpassed analyst projections, Tilray faces fundamental challenges. The company’s gross margin remains concerning at just 28.7%, raising questions about when its aggressive growth strategy will translate to sustainable profitability.

Even as its stock price struggles, Tilray continues to push forward with international expansion across key medical cannabis markets:

• Australia: Read more...